Literature DB >> 11673835

p53 over-expression identifies a subset of nodal peripheral T-cell lymphomas with a distinctive biological profile and poor clinical outcome.

E Pescarmona1, P Pignoloni, M Puopolo, M Martelli, M Addesso, C Guglielmi, C D Baroni.   

Abstract

Peripheral T-cell lymphomas (PTCL) are usually characterized by aggressive clinical behaviour and poor clinical outcome, but their biological background has not been extensively investigated to date, due to their low incidence, about 10% of all non-Hodgkin's lymphoma cases in Western countries, and also to the paucity of specific molecular-genetic abnormalities. Neverthless, there is increasing biological and clinical evidence that primary nodal PTCL should be considered separately from extra-nodal cases, but little is known about biological factors of possible clinical and prognostic impact. This immunohistochemical study has analysed the expression of p53, Mdm2, p21(WAF1), BCL-2 and p-glycoprotein (MDR-1 gene product) in a series of 45 cases of nodal peripheral T-cell lymphomas (PTCL) with 'high-grade' histology. The immunohistochemical findings were then correlated with proliferative activity and clinical outcome. p53 was over-expressed in 13 cases (28.9%). p53 positive cases showed significantly higher proliferative activity (p<0.01), more frequent expression of Bcl-2 (p<0.01) and less frequent expression of p21(WAF1) than p53 negative cases. Mdm2 and p-glycoprotein were expressed in 4/13 (30.8%) and 8/13 (61.5%) p53 positive cases respectively, and in none (0%) of the p53 negative cases (p<0.01). Analysis of the survival curves showed that p53 positive cases were associated with a significantly poorer clinical outcome than p53 negative cases, in terms of both overall survival (p=0.0032) and event-free survival (p=0.0004). Furthermore, multivariate analysis showed that p53 expression was the most important independent prognostic variable. These findings indicate that p53 over-expression identifies a subset of nodal PTCL cases with a distinctive biological profile (higher proliferative activity, less frequent expression of p21(WAF1) and more frequent expression of Bcl-2, Mdm2 and p-glycoprotein than p53 negative cases) and poor clinical outcome. The immunohistochemical analysis of p53 expression is a simple, rapid and low-cost method which may provide information of potential clinical and prognostic value in nodal peripheral T-cell lymphomas. Copyright 2001 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11673835     DOI: 10.1002/path.945

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  7 in total

1.  Linkage of expression of chemokine receptors (CXCR3 and CCR4) and cytotoxic molecules in peripheral T cell lymphoma, not otherwise specified and ALK-negative anaplastic large cell lymphoma.

Authors:  Naoko Asano; Ritsuro Suzuki; Koichi Ohshima; Yoshitoyo Kagami; Fumihiro Ishida; Tadashi Yoshino; Hiroshi Ogawa; Yasuo Morishima; Shigeo Nakamura
Journal:  Int J Hematol       Date:  2010-03-09       Impact factor: 2.490

2.  Diagnostic accuracy of a defined immunophenotypic and molecular genetic approach for peripheral T/NK-cell lymphomas. A North American PTCL study group project.

Authors:  Eric D Hsi; Jonathan Said; William R Macon; Scott J Rodig; Sarah L Ondrejka; Randy D Gascoyne; Elizabeth A Morgan; David M Dorfman; Matthew J Maurer; Ahmet Dogan
Journal:  Am J Surg Pathol       Date:  2014-06       Impact factor: 6.394

3.  Clinicopathological analysis in PTCL-NOS with CADM1 expression.

Authors:  Takeharu Kato; Hiroaki Miyoshi; Seiichiro Kobayashi; Noriaki Yoshida; Yoshitaka Imaizumi; Masao Seto; Kaoru Uchimaru; Yasushi Miyazaki; Koichi Ohshima
Journal:  Virchows Arch       Date:  2017-09-22       Impact factor: 4.064

Review 4.  Recent Advances in the Treatment of Peripheral T-Cell Lymphoma.

Authors:  Kamel Laribi; Mustapha Alani; Catherine Truong; Alix Baugier de Materre
Journal:  Oncologist       Date:  2018-04-19

5.  Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350.

Authors:  Daruka Mahadevan; Joseph M Unger; Catherine M Spier; Daniel O Persky; Fay Young; Michael LeBlanc; Richard I Fisher; Thomas P Miller
Journal:  Cancer       Date:  2012-07-25       Impact factor: 6.860

6.  CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial.

Authors:  Mary Gleeson; Clare Peckitt; Ye Mong To; Laurice Edwards; Jacqueline Oates; Andrew Wotherspoon; Ayoma D Attygalle; Imene Zerizer; Bhupinder Sharma; Sue Chua; Ruwaida Begum; Ian Chau; Peter Johnson; Kirit M Ardeshna; Eliza A Hawkes; Marian P Macheta; Graham P Collins; John Radford; Adam Forbes; Alistair Hart; Silvia Montoto; Pamela McKay; Kim Benstead; Nicholas Morley; Nagesh Kalakonda; Yasmin Hasan; Deborah Turner; David Cunningham
Journal:  Lancet Haematol       Date:  2018-05       Impact factor: 18.959

7.  Safety and efficacy of pralatrexate in the management of relapsed or refractory peripheral T-cell lymphoma.

Authors:  Annabelle L Rodd; Katherine Ververis; Tom C Karagiannis
Journal:  Clin Med Insights Oncol       Date:  2012-08-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.